Piper Sandler Rates Moderna (MRNA) buy, $77 Price Target

Piper Sandler maintains its buy rating for Moderna with a target price of $77, a 9.95% upside from the current price.

By EarningsIQ Research Desk · Published Jun 26, 2026, 1:02 PM EDT · Updated Jul 1, 2026, 6:01 AM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Piper Sandler rated Moderna, Inc. ($MRNA) "buy" with a $77 price target on June 26, 2026.

Since the rating, $MRNA is up 21.6% after 1 week, down 17.3% after 1 month and up 224.1% to date (from the $67.27 close on Jun 26, 2026).

MRNA Moderna, Inc.

$218.01 +606.45% year to date

Daily close · Oct 16, 2026

Key Points

Piper Sandler reiterated its buy rating on Moderna, Inc. (MRNA) with a price target of $77, according to analyst Edward Tenthoff on June 26, 2026.
Piper Sandler's $77 price target implies 9.95% upside from Moderna, Inc.'s ($MRNA) current $70.03 share price.
Shares of Moderna traded near $59.75 on Friday with a market cap of about $23.7 billion and a 52-week range between $22.28 and $67.74.
Insiders at Moderna, including President Stephen Hoge, have been active with recent buys and sells, while analysts have a mixed outlook with a consensus hold rating.

Get $MRNA trade alerts by text

We text you when insiders, Congress or big funds trade $MRNA. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Moderna, Inc. alert may contain errors. Disclosures

Piper Sandler has reiterated its buy rating on Moderna, Inc. (NasdaqGS: MRNA) with a price target of $77. Analyst Edward Tenthoff confirmed the rating on June 26, 2026. This comes as Moderna's shares traded around $59.75 on Friday.

Analyst rating track record

Piper Sandler vs. the S&P 500

YTD return -14.09% hypothetical

All-time return +28.50% S&P 500 +34.36%

vs. S&P 500 -5.86% behind the index

Hypothetical returns from Piper Sandler's disclosed trades, not real profit or advice. How we model this.

Other Institutional Activity in Moderna

FMR LLC significantly increased its stake in Moderna, adding 17.6 million shares to hold a total of 45.7 million shares valued at approximately $2.32 billion, marking a 62.9% increase. BlackRock, Inc. trimmed its position by 2.87 million shares, ending with 29.6 million shares worth $1.51 billion, an 8.8% decrease. Vanguard Capital Management LLC opened a new position with 22.9 million shares valued at $1.16 billion. Baillie Gifford & Co reduced its holdings by 594,638 shares, now holding about 20 million shares valued at $1.02 billion, a 2.9% decrease. Capital World Investors increased its stake by 5.87 million shares to a total of 18.7 million shares worth $949.8 million, a 45.8% increase.

Moderna, Inc. Stock Down 69.1%

Shares of Moderna traded near $59.75 on Friday. The company has a market cap of approximately $23.7 billion and a forward P/E that is not meaningful due to its lack of profitability. Moderna's beta is 1.03, indicating slightly more volatility than the market. The stock has seen a 52-week low of $22.28 and a high of $67.74. Its 50-day moving average is $50.90, and the 200-day moving average is $39.93. The company maintains a solid liquidity position with a current ratio of 2.41 and a quick ratio of 2.24, alongside a debt-to-equity ratio of 17.52.

12-month forecast

$MRNA price target

Moderna, Inc. daily closes and this analyst's $77 target. Not advice.

Recent Earnings

Moderna reported revenue of $2.22 billion, reflecting a modest growth rate of 2.6%. However, the company is currently not profitable, with a net margin of -143.6% and a return on equity of -36.6%. The next earnings announcement is scheduled for May 1, 2026.

Insider Buying and Selling at Moderna, Inc.

On June 15, 2026, President Stephen Hoge made several transactions, including a purchase of 53,336 shares at $19.15 and a planned sale of the same amount at $51.37. Additionally, on June 5, 2026, Chief Legal Officer Shannon Thyme Klinger and Chief Financial Officer James Mock each bought 11,798 shares.

Analysts Set New Price Targets

On June 26, 2026, Piper Sandler maintained its buy rating on Moderna with a price target of $77. B of A Securities kept its sell rating with a target of $34 on June 8, 2026. UBS, Goldman Sachs, Evercore ISI Group, and RBC Capital all maintained hold ratings with targets ranging from $38 to $50 in early May 2026. The consensus among analysts is a hold rating, with an average target price of $43.45 based on 20 analyst opinions.

About Moderna, Inc.

Moderna, Inc. is a biotechnology company based in Cambridge, Massachusetts. Founded in 2010, it specializes in messenger RNA medicines, developing vaccines for a range of viruses including COVID-19, RSV, and influenza. The company also works on oncology therapeutics and treatments for rare diseases. Moderna collaborates with several partners, including Merck & Co., Vertex Pharmaceuticals, and the Bill & Melinda Gates Foundation. It is led by CEO Stéphane Bancel and employs about 4,700 people.

Bottom Line

Piper Sandler's reiteration of a buy rating with a $77 target reflects confidence in Moderna's prospects, despite current financial challenges. Investors and analysts continue to watch Moderna closely, especially given the company's innovative approach to vaccines and therapeutics. As with all 13F filings and analyst updates, these ratings and holdings reflect past data and may not indicate current positions.